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1. Introduction 
During the 20th, century the awareness of the need for the ethical treatment of human 
subjects participating in experimentation has evolved. Various incidents over the years have 
sparked the creation of government entities dedicated to the regulation of human 
experimentation. This has brought about the creation of regulations whose objective is the 
protection human subjects throughout the experimentation process. These regulations call 
for many checks and balances with the objective of protecting the individual under 
experimentation through quality control procedures in the monitoring process of the 
experiment. The quality is assured through auditing the process by independent 
professionals.  This chapter will describe the history of the development of Good Clinical 
Practices (GCP) and an analysis of some applicable documents and practices developed by 
the Food and Drug Administration of the USA, and the International Conference on 
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH).  FDA (USA), EMA (EU) and Pharmaceutics and Medicines Safety Bureau (Japan) 
as well as pharmaceutical industry representatives of the USA, EU and Japan form the ICH. 
ICH guidelines provide a unified standard for designing, conducting, recording and 
reporting clinical trials involving the participation of human subjects and other necessary 
activities related to human experimentation. ICH is especially concerned with harmonizing 
the regulatory requirements of its sponsor countries; USA, EU and Japan. It describes the 
necessary activities and documentation that would allow the evaluation of the ethical 
conduct of a clinical trial and assure the quality of the information derived from such a 
study. Many countries all over the world are now including these guidelines in their 
regulations and are effectively adhering to them. 
A significant part of human experimentation is conducted in the development of new drugs 
for the treatment of human disease as well as devices and instruments used in medical 
practice. This chapter will also describe the development process, the logic behind it, the 
non-clinical testing that is necessary for the drug/device development process, the clinical 
phases of drug development, the role of the ethics committees and Institutional Review 
Boards in the approval process to conduct human experimentation as well as the role of the 
government agencies which regulate human experimentation.  
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2. Evolution of ethical conduct in human experimentation 
Since the 5th century B.C. the most prevalent code of ethical conduct for the medical 
profession has been and still is the “Hippocratic Oath”1. It is widely believed to have been 
written by Hippocrates, often regarded as the father of western medicine. The original text 
of the Hippocratic Oath is usually interpreted as one of the first statements of a moral of 
conduct to be used by physicians, assuming the respect for all human life. It has been 
modified over time in many occasions but the spirit of the concept has been preserved.  
It was not until after the end of World War II that the United States authorities conducted in 
their occupied zone several trials for war crimes committed by the Nazis in Nüremberg2. 
The trials were formally named the “Trials of War Criminals before the Nuremberg Military 
Tribunals”. They were held before US military courts, not before the International Military 
Tribunal. The defendants were accused of unethical human experimentation and other 
atrocities. On August 19th, 1947 the tribunal delivered its verdict including their opinion on 
human experimentation. The Nüremberg Code that emerged from these trials consists of 10 
points that represent a set of ethical research principles for human experimentation. The 
Nüremberg Code includes concepts like: voluntary consent of the research subject; 
experimentation with clear fruitful objectives; experimentation in humans should be 
preceded by animal experimentation; the conduct of research in humans should not produce 
physical or mental injury nor results in death of the study subjects; the experimentation 
should be conducted with a view of introducing the minimal possible risk to the individual 
during the experimentation and conducted by a qualified person. It also includes the 
concept that the subject should be at liberty to stop the experiment at any time for any 
reason. Likewise, the experimenter should be prepared to terminate the experiment if in 
their judgment there is any reasonable chance that it may harm the research subject. 
Subsequently in 1948 the World Medical Association introduced the Declaration of Geneva 3 
as a modernization of the Hippocratic Oath. It was designed as a formulation of that oath's 
moral truths that could be comprehended and acknowledged modernly.  The Declaration of 
Geneva has been amended in 1968, 1984, 1994, 2005 and 2006. 
Another important historical document addressing human experimentation is the 
Declaration of Helsinki4 adopted in 1964 by the World Medical Association in Helsinki, 
Finland.  It is a set of ethical principles for the medical community specifically related to 
human experimentation and is widely regarded as a cornerstone document for human 
research. It has been revised six times since its adoption, the last revision being in 2008. The 
Declaration of Helsinki adopted the ten principles first stated in the Nüremberg Code and 
tied them to the Declaration of Geneva.  It addresses clinical research reflecting the changes 
in medical practice. Its various revisions introduced the concept of independent review 
committees, now known as Institutional Review Board or Independent Ethics Committees; 
the management of the inclusion of minors in clinical research and the recognition of 
vulnerable groups; addressed the use of placebos; and the inclusion of human volunteers in 
clinical trials. This document was not meant to be legally binding but has influenced 
national and regional regulation and legislation around the world. It introduced the concept 
that ethical considerations must take precedence over laws and regulations. 
In the USA, the Belmont Report5 was created by the now named Department of Health and 
Human Services with the title "Ethical Principles and Guidelines for the Protection of 
Human Subjects of Research". The report was issued in April 1979 prompted in part by 
problems arising from the Tuskegee Syphilis Study (1932-1972). The Tuskegee Syphilis 
Study was designed to observe the clinical evolution of syphilis. The patients, 399 
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impoverished Black individuals from Macon county, Alabama, who thought they were 
receiving free health care from the government were never told they had syphilis nor were 
they treated for it. The Belmont Report incorporates the principles of the Nuremberg Code, 
the Declaration of Geneva and the Declaration of Helsinki. These documents influenced 
significantly the legislation and creation of regulations for the ethical conduct of human 
experimentation in the USA.  Sections 45 (government sponsored studies, 45 CFR) and 21 
(private and industry sponsored studies, 21 CFR) of the Code of Federal Regulations (CFR) 
base many of their regulations on these important ethical documents and have influenced in 
many important ways human experimentation in the US and around the world.  
3. Regulatory environment 
The U.S. Food and Drug Administration (FDA) 6 was created in 1906 by the Federal Food, 
Drug, and Cosmetic Act, the Wiley Act. The purpose was to prevent the manufacturing, 
sale, or transportation of adulterated or misbranded or poisonous or deleterious foods, 
drugs, medicines, and liquors. The FDA evolved over the years to require manufacturers to 
submit a New Drug Application (NDA) for each newly introduced drug and provide data 
that demonstrates the safety of the product (1938), and later (1962) to establish efficacy, in 
order to show that the products were effective for their claimed indication. Several 
amendments to the law have followed to reflect the evolution and emerging issues in the 
drug development and approval process, which remain today in the crossroads where 
science, medicine, politics and business intersect. Because a new drug approval is based 
largely on clinical data obtained by experiments in humans, the FDA has vested significant 
effort in ensuring the quality of the clinical data and the conditions under which they are 
obtained. The set of regulations and guidelines the FDA publishes constitute what is 
collectively known as good clinical practices or GCP. Through these FDA sets the minimum 
standards for the conduct of clinical trials, the collection of data and data management and 
reporting of clinical studies. 
The European Medicine Agency, EMA7 (formerly known as EMEA, European Agency for 
the Evaluation of Medicinal Products), was founded in 1995 and is a decentralized agency of 
the European Union responsible for the scientific evaluation of medicines developed by 
pharmaceutical companies for use in the European Union. Its main function is the 
promotion and protection of public human and animal health, through the evaluation and 
supervision of medicines for human and animal use. They are responsible for the evaluation 
of European Marketing Authorizations for human and veterinary use medicines. The 
agency monitors the safety of marketed products and provides scientific advice to 
companies on the development of new medicines.  The agency constantly works to forge 
close ties with partner organizations around the world, including the World Health 
Organization, the FDA and the other regulatory authorities. 
In Japan the Pharmaceuticals and Medical Devices Agency (PMDA) 8 working with the 
Ministry of Health implements measures for securing the efficacy and safety of drugs, 
cosmetics and medical devices. The PMDA also has forged close ties with other regulatory 
agencies, namely the EMA and FDA as partners in the formation of the International 
Conference on Harmonization (ICH).   
The International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) 9 was created in 1990. This organization brings 
together the regulatory authorities and pharmaceutical industry of Europe, Japan and the 
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US. The purpose is to discuss scientific and technical aspects of drug registration with the 
goal of harmonizing drug development and registration across the world. The Global 
Cooperation Group of this organization has been working to harmonize the increasingly 
global approach to drug development, so that the benefits of international harmonization 
for better global health can be realized worldwide. ICH's mission is to achieve greater 
harmonization to ensure that safe, effective, and high quality medicines are developed and 
registered in the most resource-efficient manner. ICH has developed a series of guidelines to 
help regulate the clinical drug development process. The instruments developed include a 
standardized medical terminology system (MedDRA) to use in the capturing, registering, 
documenting and reporting adverse events during human experimentation. ICH maintains, 
develops and distributes MedDRA. ICH also developed a standardized package for the 
submission of new drug applications, the Common Technical Document (CTD) which has 
been adopted around the world as the gold standard for new medical products submissions. 
The CTD assembles all the quality, safety and efficacy information required for regulatory 
submissions in a common format to facilitate the regulatory review process. The CTD has 
simplified the assembly of the regulatory packages since reformatting for submissions to 
different regulatory agencies is not necessary anymore. Another area where ICH has 
worked to improve is international electronic communication by evaluating and 
recommending Electronic Standards for the Transfer of Regulatory Information (ESTRI). 
ESTRI has developed recommendations for electronic individual case safety reports and 
electronic CTDs. Furthermore, ICH has developed guidelines to standardize and harmonize 
the areas involved in the drug development process.  These include guidelines on quality of 
the product being developed; on safety focusing on nonclinical studies to uncover potential 
risks for humans; on efficacy, which is concerned with the design, conduct and safety 
clinical trials; and other guideless like the ones developed by ESTRI. The clinical guidelines 
include clinical safety (E1-2), clinical study reports (E3), dose response studies (E4), ethnic 
factors (E5), Good Clinical Practice (E6), clinical trials (E7-11), clinical evaluation by 
therapeutic category (12), clinical evaluation (E14), and pharmacogenomics (E15-16). The 
GCP (E6) document describes the responsibilities and expectations of all participants in the 
conduct of clinical trials, including investigators, monitors, sponsors and IRBs. It is one of 
several GCP guidelines published by various organizations, like the World Health 
Organization (WHO), Pan American Health Organization (PAHO), FDA and EMA. ICH’s 
E6 is the GCP guideline most commonly accepted worldwide. It has been adopted by many 
countries in their regulations and accepted as the gold standard of GCP for clinical drug 
development. We will discuss E6 in more detail. 
4. Nonclinical drug testing 
Animal testing is an imperfect predictor of drug activity in humans. It constitutes the best 
practical experimental models for identifying and measuring the pharmacologic activity 
of the drug and predicting its effects in humans. In vivo and in vitro animal testing is the 
first major activity in the drug development process. The purpose is to characterize the 
toxicology, pharmacokinetic activity, and pharmacological activity of the candidate 
compounds prior to administration to human beings. FDA (21CFR58) as well as ICH (S 
guidelines) have developed standards for such testing. Initially, short-term effects are 
evaluated to decide if the drug is sufficiently safe for administration to humans and at 
what dose should the human testing start. As the drug development in human beings 
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progresses, additional animal studies are conducted. These animal studies include long-
term drug administration, and specialized animal tests are conducted to support longer 
administration in humans. These experiments allow the observation of drug effects that 
would be impractical or unethical to study in humans. Researchers can observe the effects 
of the compound over the lifespan of an animal, test dose responses and maximum doses; 
assess the effects on reproduction, pregnancy and the embryos; effects on genes; assess 
potential for carcinogenicity; evaluate mechanisms of action of the drug; and characterize 
the site, degree and duration of action of the compound. Regulatory agencies are involved 
in determining the amount and type of animal testing required to initiate drug 
development in humans as well as the requirements to support the whole clinical 
development program.  
The regulatory agencies, specifically FDA, set the minimum standards for laboratories 
conducting these nonclinical tests through the publication and enforcement of Good 
Laboratory Practice (GLP)10. To ensure the quality and integrity of the data derived, 
nonclinical laboratories are required to implement quality systems to conduct their 
experiments and to abide by the animal welfare laws of the country. GLPs establish basic 
standards for the conduct and reporting of non clinical safety testing, including the 
organization of the laboratory, personnel qualifications, physical structure of the facility, 
equipment, maintenance procedures, and operating procedures. It requires the use of a 
written protocol and its structure, including its purpose, who is sponsoring the study, 
procedure for identification and evaluation of the test animals or test system. GLP details 
how to report nonclinical studies, the storage and retrieval of records and data, and the 
retention of records. FDA conducts inspections to monitor compliance with GLP 
requirements. Nonclinical laboratories may be disqualified if the laboratory facility fails to 
comply with the regulations, and the noncompliance affects adversely the results of the 
study. 
In addition, FDA may provide advice to sponsors on the adequacy of the nonclinical testing 
plans before animal testing has begun, and evaluate independently the results and 
conclusions of the nonclinical testing. FDA has developed guidances for nonclinical testing 
also. Other regulatory authorities, namely European Community and Japan, have also 
developed their testing standards. ICH has stepped in in an effort to harmonize these 
standards with the Safety guidelines (S). 
The basic toxicology studies undertaken to identify and measure a drug’s adverse effects in 
the short- and long-term may include any or all of the studies shown in table 1 depending 
on the drug, intended use and duration of exposure in clinical trials (Table 1). 
The responsibility of the conduction of these animal experiments falls on the sponsor, the 
animal laboratory and the regulatory authorities. Quality systems are required to guarantee 
the quality of the data generated.  The Sponsor monitors the study and conducts audits, the 
laboratory needs to have proper standard operating procedures and guidelines in 
accordance with the regulations and prevailing laws as well as a quality group to ensure 
compliance with said regulations and laws, and the regulatory authorities perform 
inspections to make sure the regulations and laws are being complied with.  
5. The clinical phases of drug development 
In the FDA regulations and regulations by health authorities around the world accept 3 
phases of drug development11. A fourth phase is frequently included during the post  
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Acute toxicity studies 
Measure the short-term adverse effects of one of more 
doses administered over no more than 24 hours. Provide 
information on appropriate dosage for multiple dose 
studies, potential target organs, timeline of drug induced 
effects, species specific toxicity, potential acute toxicity 
in humans and estimate the safe acute dose for humans. 
Subacute or subchronic 
toxicity studies 
Evaluate toxic potential over 14 to 90 days depending on 
the proposed clinical indication and duration of 
exposure. They are designed to assess the progression 
and regression of drug induced lesions. 
Chronic toxicity studies 
Determine the risk in relation to the anticipated dose and 
duration of treatment, potential target organs, 
reversibility of observed toxicity and the no observed 
effect level. These studies last 180 days to 1 year of 
exposure. 
Carcinogenicity studies 
To observe the generation of malignant tumors in 
animals.  Generally they are required for drugs which 
are intended to be used for chronic conditions for 6 
months or more, or to be intermittently  used over the 
years for chronic or intermittent conditions. These 
studies are usually in rodents and last for 2 years. 
Special toxicity studies 
These are studies appropriate for specific formulations, 
route of administration, or conducted in particular 
animal models relevant to a human condition, disease or 
age. They include immunotoxicity studies. 
Reproductive toxicity studies 
For drugs to be used in women of childbearing potential. 
They include fertility and general reproductive 
performance, teratology and perinatal/postnatal 
development. 
Genotoxicity studies 
Mutagenicity studies. Are used to assess the likelihood 
of the drug causing genomic damage that could induce 
cancer development. 
Toxicokinetic studies 
Used to describe the systemic exposure achieved in 
animals and its relationship to the drug concentration, 
dose and time course of the toxic effect. The purpose is 
to contribute in the assessment of the relevance of these 
findings to clinical safety, and support the choice of 
species and dose regimen in other nonclinical studies as 
well as the design of subsequent nonclinical studies. 
Table 1. Basic Nonclinical Toxicology Studies. 
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approval period. These are not mandates that determine the specific structure or design of 
clinical trials. Although these phases are in general to be conducted sequentially, frequently 
they overlap. Clinical development programs commonly proceed in the following stages: 
5.1 Phase I  
This is the phase where initial introduction of an investigational product to humans.  The 
drug is administered cautiously to a few patients or normal human volunteers (usually less 
than 80), to gain an understanding of the pharmacology, and basic safety of the drug, 
including tolerability, activity, pharmacodynamics, pharmacokinetics, mechanism of action 
in humans and optimal route of administration. Drug metabolism, structure-activity 
relationships and studies in which investigational drugs are used as research tools to 
explore biological phenomena or disease processes are also included in this phase. The first 
evidence of the drug efficacy in humans may also be observed in these phase. Subjects are 
monitored very closely. The studies in Phase II are designed based on the results obtained 
during this phase. 
5.2 Phase II  
In this phase a small group of patients are tested, usually 100 to 200, who suffer from the 
condition the drug is intended to treat or diagnose. The studies include well controlled, 
closely monitored trials. The investigational product is administered with the objective of 
increasing the understanding of the safety profile and the initial observations on the efficacy 
of the drug in the proposed disease. In this phase the aim is to establish a foundation for the 
phase III trials. The information gathered includes dose, dose regimen and fine tuning of the 
target population.  
5.3 Phase III  
The drug in this phase is used in much larger groups of patients, several hundred or 
thousands, who suffer from the condition that the compound is supposed to treat. This 
phase includes controlled and uncontrolled studies. The idea is to gather additional safety 
and efficacy information to determine the benefit-risk ratio of the drug. In this phase the 
trials follow more rigorous standards since they will serve as the primary basis for the 
approval of the drug to be marketed. 
5.4 Phase IV 
In addition to these 3 phases, regulatory authorities may require additional studies after 
approval to clarify some finding observed during the development program or to produce 
additional safety data, or treat special populations (e.g. the elderly, patients with renal 
function impairment, children, etc.). In a general sense the clinical development process 
continues long after the drug has been approved for marketing. Collection and evaluation of 
adverse experiences and other information collected while the drug is in the market 
provides the sponsor and regulatory authorities of a continuous flow of data that allows 
ongoing review and reassessment of safety and efficacy of the drug. The concept of risk 
minimization action plans have been introduced recently. Risk minimization action plans 
are strategic plans to minimize a drug’s known risks and for the regulatory agency to 
monitor the sponsor’s implementation of the plan. These postmarketing commitments range 
from comprehensive literature reviews to large controlled trials. These post marketing 
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studies are usually called post approval trials or phase IV trials. Phase IV trials can be 
undertaken at the request of the regulatory agency as part of a postapproval commitment, 
as a specific regulatory agency requirement, or at a company’s own decision to learn more 
about their product. 
6. Quality systems in clinical research
12
 
Many aspects of Good Manufacturing Practice (GMP) apply to the drug development 
process. Quality is a measure of the ability of a product, process, or service to satisfy stated 
or implied needs. A high quality product is one that meets these needs. For human 
experimentation, quality may apply to data generation and management, or, the processes 
involved in the implementation of the trials. Quality systems for human experimentation are 
the formalized practices, e.g. monitoring programs, auditing programs, complaint handling 
systems, etc., for periodically reviewing the adequacy of the activities and practices during 
human experimentation, and for revising such activities and practices so that data and 
process quality are maintained. For human experimentation GCPs are the basis for 
implementation of quality systems through quality management. This is done through the 
coordination of activities by the sponsors of the experiments, the clinical investigators and 
their staff, the institutional review boards and independent ethics committees, and by 
regulators to direct and control the operations with respect to quality. Quality management 
consists of three components: quality control, quality assurance, and quality improvement. 
In the case of human experimentation, Quality Control is the steps taken during the 
implementation of the clinical trial to ensure the quality of the data generated and the 
processes involved. These include investigator supervision, sponsor monitoring, and any 
review by the regulatory authorities, to ensure that the trial meets the protocol and 
procedural requirements and is reproducible. Quality Assurance is the systematic process 
to determine whether the quality control system is working and effective.  In clinical trials 
this is usually done by the sponsor through independent auditing of quality control 
activities, and also by the regulatory authorities through inspection of the quality systems 
and activities. 
With the knowledge obtained from the quality assurance, audits and activities changes are 
made to the systems and activities with the purpose of increasing the ability to fulfill the 
quality requirements for the moment and in the future. This process can be called Quality 
Improvement. 
Another activity central to maintaining and improving quality in clinical trial is the process 
of monitoring.  Monitoring is a quality control activity conducted by the sponsor or a 
representative of the sponsor. The purpose is to ensure that the research data are accurate, 
complete, and verifiable from source documents. GCP guidelines (ICH E6)9 defines 
monitoring as “the act of overseeing the progress of a clinical trial, and of ensuring that it is 
conducted, recorded, and reported in accordance with the protocol, standard operating 
procedures, good clinical practices, and the applicable regulatory requirements.” Monitors 
usually compare the data in the case report forms designed for the study and the source 
documents, i.e., with the medical chart of the patient, physician notes, laboratory results, etc.  
Monitors also make sure that the activities related to protecting the rights and welfare of the 
study subjects were carried out appropriately. On the other hand, auditing is an 
independent quality assurance activity used by the sponsor to evaluate the effectiveness of 
the monitoring program. Auditing procedures are similar to the monitoring activities. The 
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difference is that monitoring occurs only during the execution of the clinical study, auditing 
occurs at any time during or after the clinical study is completed. In addition to quality 
audits there are inspections conducted by the regulatory authority(ies). An inspection is the 
act of conducting an official review of documents, facilities, records, and any other resources 
the authorities deem related to the clinical study. The inspection may be at the clinical trial 
site, at the sponsor’s facilities, and/or at the Contract Research Organization (CRO) 
facilities, or at any other establishment the authorities deem appropriate. CROs are 
organizations which are normally contracted by sponsors to monitor their clinical studies.  
CROs may also conduct a complete development program for a sponsor on occasions, or 
deliver part of the activities related to the development of the investigational product. The 
purpose of monitoring is to determine if the research was conducted in compliance with 
national and local laws and regulations for the conduct of research and the protection of 
human subjects. 
All parties involved in human experimentation (sponsors, clinical investigators, Institutional 
Review Boards/Independent Ethics Committees, and regulatory authorities) need to adopt 
and implement quality systems for the processes and activities they are responsible for. 
This includes clinical research facilities. Clinical research should include Quality Systems to 
measure the quality of clinical research through the use of standard operating procedures 
(SOPs), study protocol compliance, internal monitoring and the sponsor’s monitoring 
activities. This is accomplished through training of the personnel involved in clinical trial 
activities, internal and external audits, and accountability of the personnel. 
A Typical quality system would include production and process control, equipment and 
facilities control; records, documents and change controls; material controls, design controls 
and corrective and preventive action.  (Figure 1). This system can easily be adapted for the 
development of medical devices. 
 
 
Fig. 1. Typical quality system. This system can easily be adapted to a medical device 
development facility. 
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A Quality System for an investigational clinical center may be also adapted from this 
diagram to include the following areas under the control of the clinical investigator  
(Figure 2): 
- Facility and Equipment Evaluation and Documentation 
- Source Documentation Generation, Integrity and Retention 
- Consent Process and Documentation 
- Safety Management and Reporting Processes and Documentation 
- Investigational Product Accountability and Integrity and Documentation 
- Site Staff Qualifications, Training, and Documentation 
- Corrective and Preventive Action Development and Implementation Facility 
 
 
Fig. 2. The organization of a clinical investigational site. 
These represent the activities required in a well run clinical investigational site. The 
investigator is responsible for all activities. The site should have guidelines and/or standard 
operating procedures for each these areas and activities. In addition, the investigator should 
have sufficient personnel who are properly trained and qualified to conduct these activities. 
It is also important that the facility are appropriate in size and configuration to 
accommodate all these areas. 
7. FDA Bioresearch monitoring 
12
  
The Food and Drug Administration's (FDA) bioresearch monitoring program (BIMO) was 
established in 1977 with input from the drug, biologics, medical device, veterinary medicine, 
and food areas. Chapter 48 of the FDA’s Compliance Program Guidance Manual is 
dedicated to Bioresearch Monitoring and delineates the inspection and reporting procedures 
for studies under FDA jurisdiction. The stated objectives of the bioresearch monitoring 
program are: to protect the rights, safety, and welfare of subjects involved in FDA-regulated 
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clinical trials; verify the accuracy and reliability of clinical trial data submitted to FDA in 
support of research or marketing applications; and assess compliance with FDA’s 
regulations governing the conduct of clinical trials. The purpose of the program is to 
provide instructions for FDA’s field personnel for conducting such inspections. 
BIMO developed compliance programs to provide uniform guidance and specific 
instructions for inspections of clinical investigators, sponsors and monitors, in-vivo 
bioequivalence facilities, Institutional Review Boards, and nonclinical laboratories involved 
in the testing of investigational products. The purpose of these programs is to adapt a 
Quality System framework for the oversight and management of clinical studies.  
The most useful elements of a quality system that applies to clinical studies are: corrective 
and preventive action (CAPA) and management controls. CAPA procedures can be adapted 
to ensure effective and efficient clinical study management. 
The application of CAPA to clinical research activities involve: 
- Identification of non-conformances, e.g. protocol deviations, errors of omission or 
transcription. 
- Investigation of the cause of the problem identified 
- Identification of the actions needed to correct and prevent recurrence of the problem 
- Verification that the corrective action is effective 
- Making sure that the information is appropriately disseminated 
- Submission of the information for management review on problems identified and 
actions taken 
- Documentation of the process 
Management controls involve the appointment of a management representative responsible 
for the research, in this case the investigator or sub Investigator, and to conduct 
management reviews. 
Figure 3 shows the relationship between CAPA, management reviews and audits, external 
(sponsor monitoring, third party or FDA) and internal through monitoring internal 
activities. 
 
              CAPA 
 
         AUDITS            MANAGEMENT  
                REVIEW 
Fig. 3 Relationship between CAPA, Management Reviews and Audits. 
Although FDA inspections are focused on clinical investigators, they are of great importance 
to sponsors. The inspections are designed to determine how well sponsors performed their 
responsibilities for the conduct of the study; should the inspections uncover serious 
problems it may result in rejection of the data essential for drug approval. As a result the 
sponsor may face inspections and compliance actions if it is found to have worked with 
noncompliant investigators and did not take corrective action. 
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8. Good clinical practice (E6)
9 
Good Clinical Practices (GCP) is not a set of instructions on how to develop a product or 
how to design human experiments. GCP is a series of general principles that must be 
observed during the conduct of human experimentation. This GCP guideline provides a 
unified standard for designing, conducting, recording, and reporting clinical trials that 
involve human subjects. Compliance with this guideline provides public assurance that the 
rights, well-being, and confidentiality of the trial subjects are protected and that the results 
of the study are credible. GCP are part of the quality systems to cover testing of medicinal 
products and devices, and conducting clinical studies in human beings. Their objective is to 
provide a unified standard for the European Union, Japan, and the United States, with 
consideration to existing GCPs of Australia, Canada, the Nordic countries as well as the 
World Health Organization, and to facilitate the mutual acceptance of clinical data by the 
regulatory authorities. It includes also the minimum information that should be included in 
the information to the investigator, which are the documents considered essential, their 
purpose, and how to file them. Many countries around the world have adopted these 
guidelines as their own. The ICH guideline on GCP (E6) outlines the 13 principles of good 
clinical practices. These principles are in line with the Nüremberg Code, the Declaration of 
Helsinki and the Belmont Report. These guidelines should be adopted by IRBs/IECs, 
sponsors, and clinical investigators as well as regulatory authorities who oversee or conduct 
clinical trials. 
8.1 Principles of GCP 
1. Clinical studies should be conducted according to ethical principles 
2. Foreseeable risks and inconveniences should be weighed against anticipated benefit to 
the subjects 
3. The rights, safety and well-being of the trial subjects should be the most important 
consideration and prevail over scientific or societal interests. 
4. Available preclinical and clinical information on a product should be adequate to 
support the proposed trial 
5. A clinical trial should be scientifically sound and described in a clear detailed protocol. 
6. A clinical trial should be conducted in compliance with a protocol previously approved 
by an IRB/IEC. 
7. Medical care given to, and decisions made on behalf of, trial subjects should be always 
the responsibility of a qualified physician or qualified dentist.  
8. Each individual involved in conducting the trial should be qualified by education, 
training, and experience to perform his/her respective tasks. 
9. Freely given informed consent should be obtained from every study subject prior to 
clinical trial participation. 
10. All clinical trial information should be recorded, handled, and stored in a way that 
allows accurate reporting, interpretation, and verification. 
11. The confidentiality of the records should be protected 
12. The investigational products should be manufactured, handled, and stored in 
accordance with applicable good manufacturing practices (GMP), and used in 
accordance with the approved protocol. 
13. Systems with procedures that assure the quality of every aspect of the trial should be 
implemented. 
The GCP outline the duties of the IRBs/IECs, sponsors, and the clinical investigators.  
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8.2 Independent Ethics Committees (IECs) and Institutional Review Boards (IRBs) 
Their main responsibility is to safeguard the rights, safety, and wellbeing of all trial subjects, 
with special attention to the inclusion of vulnerable subjects to the trial. The IRB/IEC is 
required to have standard operating procedures and maintain written records of their 
meeting and decisions. The composition and authority under which the IRB was established 
should be documented in writing. All meetings, notification to members, and schedules 
should be disseminated in writing. In summary all information and documentation of 
activities should be documented and transparent.  
The IRB/IEC should consider the qualifications of the investigator, ensure that all subjects 
have freely provided their informed consent to be included in the study, ensure that 
payments to the subject for participation in the trial are not coercive or exercise undue 
influence, and continuously review the progress of the experimentation at intervals 
appropriate to the degree of risk to human subjects, but at least once per year. The IRB can 
request additional information if in the judgment of the IRB members the additional 
information would add meaningfully to the protection of rights, safety and/or well-being of 
the trial subjects. The IRB should always determine that a protocol or the information 
provided adequately addresses relevant ethical concerns and meets applicable regulatory 
requirements.  
The IRB is usually composed of at least 5 members, at least one member whose primary area 
of interest is nonscientific, and at least one member who is independent of the trial site. The 
investigator may provide information on any aspect of the trial but should not participate in 
deliberations or in the vote, or opinion of the IRB. 
8.3 The informed consent process 
For the implementation of the informed consent the investigator should comply with all 
regulatory requirements and adhere to GCP and the ethical principles originating in the 
Declaration of Helsinki. The subject should be thoroughly informed of the experiment to be 
conducted, the risks and the potential benefits. Ample time should be given to the subject to 
make his/her decision to participate in the study. It should be very clear what the 
experimentation is all about. No coercion should be applied on the potential study subject.  
The informed consent document should include explanations of the following: 
- The trial involves research, and some parts of it are experimental. 
- The purpose of the trial and the voluntary nature of the subject’s participation. 
- The treatment and probability for random assignment to treatment. That is in a double 
blinded study neither the patient nor the investigator may know which treatment is 
being administered. 
- The trial procedures. Including potential for risky procedures and their potential 
consequences.  
- The subject’s responsibility to follow the indications from the investigator. 
- Reasonable foreseeable risks or inconveniences to the subject, and embryo, fetus or 
nursing infant, if applicable. 
- Reasonable expected benefits. 
- Alternative forms of treatment for the condition under investigation and their potential 
risks and benefits. 
- Compensation for trial related injury. 
- Payment to the subject, if any. 
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- Expenses for the subject, if any. 
- That the subject’s original medical records may be accessed by regulatory authorities, 
IRB/IEC, the monitor and auditors for verification of the information.   
- That confidentiality will be maintained and not be made public. 
- All new information related to the trial that becomes available that may be relevant to 
the subject’s willingness to continue to participate in the trial will be forwarded to the 
subject. 
- Who to contact with questions or in the event of a trial related injury 
- Foreseeable circumstances or reasons under wich the subject’s participation in the trial 
may be terminated. 
- The duration of the trial and approximate number of subjects involved. 
8.4 The investigator 
The investigators supervise the study staff to ensure they follow established procedures for 
the conduct of the study. They should be qualified by training, education and experience to 
conduct clinical trials. The investigators should be thoroughly familiar with GCP, the 
product under investigation and the study protocol. Investigators are responsible for all 
medical decisions. In their role they obtain approval to conduct the study from the IRB/IEC; 
ensure that informed consent is obtained freely and without coercion before the study starts; 
establish and maintain the subjects’ case histories; transcribe the subjects’ medical data from 
the medical files to a case report form for the sponsor; ensure the accuracy, completeness, 
legibility, and timeliness of the data reported; promptly report all adverse events and other 
problems;  document and explain any deviations from the study protocol; be responsible for 
the accountability and proper storage as well as the use according to the protocol of the 
investigational product; and provide all required reports at the end of the study to the 
sponsor. 
Investigators should be in contact with the IRB/IEC and the sponsor frequently.  
Communications involve, 
- Before initiating the trial, obtain a written and dated approval/favorable opinion from 
the IRB/IEC to start the study 
- Provide the IRB/IEC with a copy of the information on the product under investigation 
(the Investigator’s Brochure, IB) and any amendments to the IB during the study. 
- Report promptly any serious adverse event or laboratory abnormality immediately to 
the sponsor, the regulatory authorities and the IRB/IEC, and follow up with a detailed 
written report with any additional information requested.  
- For patients who die during the study the investigator should supply the sponsors, 
regulatory authorities and the IRB/IEC with all pertinent information on the event. 
Upon completion of the trial the investigator should inform the sponsor, the IRB/IEC and 
the regulatory authorities with a summary of the trial outcome, and any other report 
required by applicable regulation. 
8.5 The sponsor 
Sponsors are responsible implementing and maintaining quality assurance and quality 
control systems with written SOPs to ensure that the trials are conducted, and data are 
generated, documented and reported in compliance with the protocol, GCP, and applicable 
regulatory requirements. Sponsors are also responsible for securing agreement from all 
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involved parties to ensure direct access to clinical trial related sites, source documents, and 
reports for the purpose of monitoring and auditing by the sponsor, CRO and regulatory 
authorities. Agreement with the investigators or any other party involved in the study 
should be in writing.  
Quality control should be applied to each stage of data handling to ensure that all data are 
reliable and have been properly processed, for securing the services of monitors to ensure 
compliance of clinical investigators and verify that the study is carried out according to the 
approved study protocol. Sponsors also audit the monitor’s performance, other quality 
control activities and systems to ensure performance. The monitors hired by the sponsor to 
review the records at the clinical centers, and report their finding to the sponsor in written 
reports of all visits and trial related communications. 
Sponsors may transfer in writing any or all their obligations to a contract research 
organization (CRO), but the ultimate responsibility for the quality and integrity of the data 
always resides with the sponsor. CROs have the same obligations as the sponsor. 
The sponsor is responsible for the medical expertise. Qualified medical personnel should be 
readily available to advise on trial related matters. An external consultant may be appointed 
for this function. 
Sponsors are responsible for the trial design, trial management, trial data handling, and 
retention of documents for the specified period required by law and regulations. They are 
also responsible for the selection of qualified investigators and to apply with the regulatory 
authorities to conduct the trial. 
Finally, the sponsor is responsible to provide insurance or indemnification to the 
investigator against claims arising from the trials, except for claims arising from malpractice 
and/or negligence. 
8.6 Regulators 
The regulators may inspect all parties who conduct or oversee clinical research and verify 
the information submitted to the regulatory authorities. Regulatory agencies inspect 
specifically clinical investigators, pharmaceutical companies, device companies, CROs, 
IRBs/IECs, as well as nonclinical laboratories, to ensure the accuracy and validity of the 
data generated, and to ensure that the rights and welfare of the research subjects are 
protected. The regulatory inspectors evaluate how well sponsors, monitors, clinical and non 
clinical investigators, CROs, and IRBs/IECs comply with the regulations. They may require 
certain conditions for a study to proceed. They develop policies and procedures for 
reviewing product applications and for the conduct of GCP inspections as exemplified by 
the FDA’s BIMO compliance programs.  
9. Conclusion 
Over the last century the scientific community has developed a better understanding of how 
to protect and respect the rights, safety and wellbeing of research subjects. For centuries the 
Hippocratic Oath was the only ethical guidance for physicians and scientists on how to treat 
subjects, and specifically research subjects. The development of Good Clinical Practice was 
the result of various incidents that resulted in the Nuremberg Code, the Declaration of 
Geneva, the Declaration of Helsinki and the Belmont Report. ICH is an attempt to 
harmonize GCP in the most advanced democracies. Today, many regulatory agencies 
around the globe use these principles to regulate human experimentation in their countries. 
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The responsibility of GCP is shared by all parties involved in human experimentation, 
investigators, sponsors, ethics commitees, regulatory authorities, and research subjects. To 
guarantee the quality and accuracy of the data generated during human experimentation 
Quality Systems have been developed and are applied around the world. 
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